Form PTO 1390 (REV 5-93) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		P32328 U.S. APPLICATION NO (If known, see 37 C.F.R. 1 5) 10/018547
INTERNATIONAL APPLICATION NO. PCT/GB00/02364	INTERNATIONAL FILING DATE 16 June 2000	PRIORITY DATE CLAIMED 16 June 1999
TITLE OF INVENTION Novel Compounds		
APPLICANT(S) FOR DO/EO/US Patrick CAMILLERI, Philippe GUEDAT,Anthony John KIRBY, and Andreas KREMER		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1 [x] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.

2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.

3. [x] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

4. [x] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. [x] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [x] has been transmitted by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).

6. [ ] A translation of the International Application into English (35 U.S.C. 371(c)(2)).

7. [ ] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] have been transmitted by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [ ] have not been made and will not be made.

8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)).

9. [ ] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. [x] An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.

12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.

13. [x] A FIRST preliminary amendment.

14. [ ] A SECOND or SUBSEQUENT preliminary amendment.

15. [x] Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/GB00/02364, filed 16 June 2000, which claims benefit from the following Provisional Application: GB 9914045.1, filed 16 June 1999.

16. [ ] A substitute specification.

17. [ ] A change of power of attorney and/or address letter.

18. [x] An Abstract on a separate sheet of paper.

19. [ ] Other items or information:

JC07 Rec'd PCT/PTO 12 DEC 2000

US APPLICATION NO. (If known, see 37 CFR 1.50) 10/018547	INTERNATIONAL APPLICATION NO. PCT/GB00/02364	ATTORNEYS DOCKET NO. P32328

20. [X] The following fees are submitted:	CALCULATIONS	PTO USE ONLY
Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):		
Search Report has been prepared by the EPO or JPO **$890.00**	**890.00**	
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) **$710.00**		
No International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) **$740.00**		
Neither International Preliminary Examination Fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....**$1,040.00**		
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4).....**$100.00**		
ENTER APPROPRIATE BASIC FEE AMOUNT =	**$890.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	**$0.00**	

Claims	Number Filed	Number Extra	Rate		
Total claims	**32 - 20 =**	**12**	**12 x $18.00**	**$216.00**	
Independent claims	**1 - 3 =**	**0**	**0 x $84.00**	**$0.00**	
Multiple dependent claims (if applicable)			**+ $280.00**	**$0.00**	
			TOTAL OF ABOVE CALCULATIONS =	**$1,106.00**	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				**$**	
			SUBTOTAL =	**$1,106.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +				**$**	
			TOTAL NATIONAL FEE =	**$1,106.00**	
				Amount to be refunded	$
				charged	$

a. ☐ A check in the amount of $____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **$1,106.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570 . A duplicate copy of this sheet is enclosed.

d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968
Facsimile (610) 270-5090

SIGNATURE
William R. Majarian
NAME
41,173
REGISTRATION NO.

"Express Mail Certificate"
"Express Mail" Mailing Label Number EL231308857US
Date of Deposit: December 12, 2001

Attorney Docket No: P32328

IN THE UNITED STATES INTERNATIONAL EXAMINING AUTHORITY

International Application No.:	PCT/GB00/02364
International Filing Date:	16 June 2000
Priority Date Claimed:	16 June 1999
Applicants for DO/US:	Camilleri, et al.
Title of Invention:	Novel Compounds

Assistant Commissioner for Patents
Box PCT
Washington D.C. 20231

FIRST PRELIMINARY AMENDMENT

Sir:

Preliminary to calculating filing fees and examining this application please amend the application as follows.

In the Specification:

Please add the following paragraph to page 1, directly under the Title of the Invention with the following paragraph:

-- CROSS REFERENCES TO RELATED APPLICATIONS--
This application is a National Stage Application filed under 35 U.S.C.§371 of PCT/GB00/02364, filed on June 16, 2000--.

After page 25, please insert the Abstract that accompanies this Preliminary Amendment.

In the Claims:

Please delete claim 32.
Please amend claims 1, 3-31.

1. (Amended) A spermine:peptide-based surfactant compound having the general structure of formula (I):



(I)

where R_1 and R_3 are hydrogen and R_2 and R_4, which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):

$$
\begin{array}{l} -\ (A1)_{p1} - (A2)_{p2} - (A3)_{p3} \\ \qquad\qquad\ \ | \\ \qquad\quad\ (A4)_{p4} \end{array} \qquad \text{(II)}
$$

where p1 is 0 to 5 and p2 is 1 to 5; and the values for p3 and p4, which may be the same or different, are from 0 to 5;
A1, A3 and A4, which may be the same or different, are amino acids selected from the group consisting of serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and A2 is an amino acid selected from the group consisting of lysine, ornithine and histidine;
and R_5 and R_6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH_2) linkage;
or
where R_1 and R_3 are hydrogen, R_2 and R_4, which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine

backbone by amide or amine bonds, and R_5 and R_6, which may be the same or different, are peptide groups of formula (II) linked to the spermine backbone by amide bonds;
and
pharmaceutically acceptable salts thereof.

3. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein in the peptide group of formula (II) p1 is 1 and p2, p3 and p4 are all 0.

4. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein in the peptide group of formula (II) p1 and p2 are both 1 and p3 and p4 are both 0.

5. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein in the peptide group of formula (II) p1 is 0 and p2, p3 and p4 are all 1.

6. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein in the peptide group of formula (II) p1 and p3 are 0, p2 is 1 and p4 is 2.

7. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein the A1 is serine.

8. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein the A2 is lysine.

9. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from the group consisting of:

—$(CH_2)_{11}CH_3$;
—$(CH_2)_{13}CH_3$;
—$(CH_2)_{15}CH_3$;
—$(CH_2)_{17}CH_3$;
—$(CH_2)_{19}CH_3$;
—$(CH_2)_{23}CH_3$;
—$(CH_2)_8CH{=}CH(CH_2)_5CH_3$;
—$(CH_2)_8CH{=}CH(CH_2)_7CH_3$;
—$(CH_2)_8CH{=}CHCH_2CH{=}CH(CH_2)_4CH_3$;
—$(CH_2)_8(CH{=}CHCH_2)_3CH_3$;
—$(CH_2)_4CH{=}CH(CH_2CH{=}CH)_3(CH_2)_4CH_3$;
—$(CH_2)_8CH{=}CH(CH_2)_5CH_3$ Trans;
—$(CH_2)_8CH{=}CH(CH_2)_7CH_3$ Trans; and
—$(CH_2)_9CHCH_3(CH_2)_7CH_3$.

10. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from the group consisting of:

—$CO(CH_2)_{10}CH_3$;
—$CO(CH_2)_{12}CH_3$;
—$CO(CH_2)_{14}CH_3$;
—$CO(CH_2)_{16}CH_3$;
—$CO(CH_2)_{18}CH_3$;
—$CO(CH_2)_{22}CH_3$;
—$CO(CH_2)_7CH{=}CH(CH_2)_5CH_3$;
—$CO(CH_2)_7CH{=}CH(CH_2)_7CH_3$;
—$CO(CH_2)_7CH{=}CHCH_2CH{=}CH(CH_2)_4CH_3$;
—$CO(CH_2)_7(CH{=}CHCH_2)_3CH_3$;
—$CO(CH_2)_3CH{=}CH(CH_2CH{=}CH)_3(CH_2)_4CH_3$;
—$CO(CH_2)_7CH{=}CH(CH_2)_5CH_3$ Trans;
—$CO(CH_2)_7CH{=}CH(CH_2)_7CH_3$ Trans;
—$CO(CH_2)_8CHCH_3(CH_2)_7CH_3$;
—$COCHOH(CH_2)_{21}CH_3$;
—~~CO~~$(CH_2)_9CH$  $CH(CH_2)_5CH_3$; and



.

11. (Amended) The compound of claim 1 having the formula:



12. (Amended) The compound of claim 1 having the formula:



13. (Amended) The compound of claim 1 having the formula:



. HCl 4

14. (Amended) The compound of claim 1 having the formula:



. HCl 4

15. (Amended) The compound of claim 1 having the formula:



16. (Amended) The compound of claim 1 having the formula:



17. (Amended) The compound of claim 1 having the formula:



18. (Amended) The compound of claim 1 having the formula:



19. (Amended) A method of introducing DNA or RNA polynucleotides or analogs thereof into a eukaryotic or prokaryotic cell *in vivo* or *in vitro* comprising contacting the cell with the compound of claim 1 and a DNA or RNA polynucleotide or analog thereof.

20. (Amended) The method of claim 19 further comprising contacting the cell with one or more supplements selected from the group consisting of:
(i) a neutral carrier; and
(ii) a complexing reagent.

21. (Amended) The method of claim 20 wherein the neutral carrier is dioleoyl phosphatidylethanolamine (DOPE).

22. (Amended) The method of claim 20 wherein the complexing reagent is PLUS reagent.

23. (Amended) The method of claim 20 wherein the complexing reagent is a peptide comprising basic amino acids.

24. (Amended) The method of claim 23 wherein the peptide consists of basic amino acids.

25. (Amended) The method of claim 23 wherein the basic amino acids are selected from lysine and arginine.

26. (Amended) The method of claim 23 wherein the peptide is polylysine or polyornithine.

27. (Amended) The method of claim 19 wherein the polynucleotides are introduced into a cell to achieve an antisense knock-out effect.

28. (Amended) The method of claim 19 wherein the polynucleotides are introduced into a cell for gene therapy.

29. (Amended) The method of claim 19 wherein the polynucleotides are introduced into a cell for genetic immunization (for the generation of antibodies) in whole organisms.

30. (Amended) The method of claim 19 wherein the polynucleotides are introduced into a cell in culture.

31. (Amended) A method of introducing a polynucleotide or anti-infective compound into a prokaryotic or eukaryotic organism for use in anti-infective therapy, the method comprising contacting the organism with the compound of claim 1 and a polynucleotide or anti-infective compound.

REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/GB00/02364 into the U.S. National Phase of prosecution. Claim 32 has been cancelled. Claims 1, 3-31 have been amended to eliminate multiple dependencies and to comply with proper U.S. claim format. Furthermore, attached hereto is a marked-up version of the changes made to the application by the current preliminary amendment. The attached page is captioned, "**Version with markings to show changes made.**"

Respectfully submitted,

William R. Majarian
Attorney for Applicants
Registration No. 41,173

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968
Facsimile (610) 270-5090

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

CROSS REFERENCES TO RELATED APPLICATIONS

This newly added paragraph to the specification is solely to incorporate continuing application data. No changes have been made. Therefore, a marked up version is not required.

The newly added page to the specification is solely to incorporate the Abstract page. No changes have been made, therefore, a marked up version is not required.

In the claims:

Please cancel claim 32.
Please amend claims 1, 3-31.

1. (Amended) A spermine:peptide-based surfactant compound having the general structure of formula (I):



(I)

where R_1 and R_3 are hydrogen and R_2 and R_4, which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):

$$\begin{array}{l} -\ (A1)_{p1} - (A2)_{p2} - (A3)_{p3} \\ \qquad\qquad\ \ | \\ \qquad\quad\ (A4)_{p4} \end{array}$$

(II)

where p1 is 0 to 5 and p2 is 1 to 5; and the values for p3 and p4, which may be the same or different, are from 0 to 5;

A1, A3 and A4, which may be the same or different, are amino acids selected from the group consisting of serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and

A2 is an amino acid selected from the group consisting of lysine, ornithine and histidine;

and R_5 and R_6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH_2) linkage;

or

where R_1 and R_3 are hydrogen, R_2 and R_4, which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by amide or amine bonds, and R_5 and R_6, which may be the same or different, are peptide groups of formula (II) linked to the spermine backbone by amide bonds;

[or] and

[a salt, preferably a] pharmaceutically acceptable salts thereof.

3. (Amended) A spermine:peptide-based surfactant compound according to claim 1 [or 2] wherein in the peptide group of formula (II) p1 is 1 and p2, p3 and p4 are all 0.

4. (Amended) A spermine:peptide-based surfactant compound according to claim 1 [or 2] wherein in the peptide group of formula (II) p1 and p2 are both 1 and p3 and p4 are both 0.

5. (Amended) A spermine:peptide-based surfactant compound according to claim 1 [or 2] wherein in the peptide group of formula (II) p1 is 0 and p2, p3 and p4 are all 1.

6. (Amended) A spermine:peptide-based surfactant compound according to claim 1 [or 2] wherein in the peptide group of formula (II) p1 and p3 are 0, p2 is 1 and p4 is 2.

7. (Amended) A spermine:peptide-based surfactant compound according to [any one of] claim[s] 1 [to 6] wherein the A1 is serine.

8. (Amended) A spermine:peptide-based surfactant compound according to [any one of] claim[s] 1 [to 6] wherein the A2 is lysine.

9. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from the group consisting of:

—$(CH_2)_{11}CH_3$;
—$(CH_2)_{13}CH_3$;
—$(CH_2)_{15}CH_3$;
—$(CH_2)_{17}CH_3$;
—$(CH_2)_{19}CH_3$;
—$(CH_2)_{23}CH_3$;
—$(CH_2)_8CH{=}CH(CH_2)_5CH_3$;
—$(CH_2)_8CH{=}CH(CH_2)_7CH_3$;
—$(CH_2)_8CH{=}CHCH_2CH{=}CH(CH_2)_4CH_3$;
—$(CH_2)_8(CH{=}CHCH_2)_3CH_3$;
—$(CH_2)_4CH{=}CH(CH_2CH{=}CH)_3(CH_2)_4CH_3$;
—$(CH_2)_8CH{=}CH(CH_2)_5CH_3$ Trans;
—$(CH_2)_8CH{=}CH(CH_2)_7CH_3$ Trans; and
—$(CH_2)_9CHCH_3(CH_2)_7CH_3$.

10. (Amended) A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from the group consisting of:

—$CO(CH_2)_{10}CH_3$;
—$CO(CH_2)_{12}CH_3$;
—$CO(CH_2)_{14}CH_3$;
—$CO(CH_2)_{16}CH_3$;
—$CO(CH_2)_{18}CH_3$;
—$CO(CH_2)_{22}CH_3$;
—$CO(CH_2)_7CH{=}CH(CH_2)_5CH_3$;
—$CO(CH_2)_7CH{=}CH(CH_2)_7CH_3$;
—$CO(CH_2)_7CH{=}CHCH_2CH{=}CH(CH_2)_4CH_3$;
—$CO(CH_2)_7(CH{=}CHCH_2)_3CH_3$;
—$CO(CH_2)_3CH{=}CH(CH_2CH{=}CH)_3(CH_2)_4CH_3$;
—$CO(CH_2)_7CH{=}CH(CH_2)_5CH_3$ Trans;
—$CO(CH_2)_7CH{=}CH(CH_2)_7CH_3$ Trans;
—$CO(CH_2)_8CHCH_3(CH_2)_7CH_3$;
—$COCHOH(CH_2)_{21}CH_3$;
—~~CO~~$(CH_2)_9CH$(CH_2)$CH(CH_2)_5CH_3$; and

$$\begin{array}{l} \\ \\ \\ \mathrm{COCH}-(\mathrm{CH_2})_{10}\mathrm{CH_3} \\ \quad\ \mathrm{CO(CH_2)_{12}CH_3} \end{array}$$

11. (Amended) The compound of claim 1 having the formula:



12. (Amended) The compound of claim 1 having the formula:



13. (Amended) The compound [GSC1 of formula] of claim 1 having the formula:



. HCl 4

14. (Amended) The compound [GSC4 of formula] of claim 1 having the formula:



. HCl 4

15. (Amended) The compound [GSC40 of formula] of claim 1 having the formula:



16. (Amended) The compound [GSC42 of formula] of claim 1 having the formula:



17. (Amended) The compound [GSC2 of formula] of claim 1 having the formula:



18. (Amended) The compound [GSC12 of formula] of claim 1 having the formula:



19. (Amended) [The use of a spermine:peptide-based surfactant compound as defined in any one of claims 1 to 15 in facilitating transfection of] A method of introducing DNA or RNA

polynucleotides or analogs thereof into a eukaryotic or prokaryotic cell *in vivo* or *in vitro* comprising contacting the cell with the compound of claim 1 and a DNA or RNA polynucleotide or analog thereof.

20. (Amended) The method of claim 19 [use of a spermine:peptide-based surfactant compound according to claim 19 wherein the compound] further comprising contacting the cell [is used in combination] with one or more supplements selected from the group consisting of:
(i) a neutral carrier; [or] and
(ii) a complexing reagent.

21. (Amended) The method of [use according to] claim 20 wherein the neutral carrier is dioleoyl phosphatidylethanolamine (DOPE).

22. (Amended) The method of [use according to] claim 20 wherein the complexing reagent is PLUS reagent.

23. (Amended) The method of [use according to] claim 20 wherein the complexing reagent is a peptide comprising [mainly] basic amino acids.

24. (Amended) The method of [use according to] claim 23 wherein the peptide consists of basic amino acids.

25. (Amended) The method of [use according to] claim 23 [or 24] wherein the basic amino acids are selected from lysine and arginine.

26. (Amended) The method of [use according to] claim [24] 23 wherein the peptide is polylysine or polyornithine.

27. (Amended) The method of [use according to any one of] claim[s] 19 [to 26] wherein the [oligonucleotides or] polynucleotides are [transferred] introduced into a cell[s] to achieve an antisense knock-out effect.

28. (Amended) The method of [use according to] claim 19 wherein the [oligonucleotides or] polynucleotides are [transferred] introduced into a cell[s] for gene therapy.

29. (Amended) The method of [use according to] claim 19 wherein the [oligonucleotides or] polynucleotides are [transferred] introduced into a cell[s] for genetic [immunisation] immunization (for the generation of antibodies) in whole organisms.

30. (Amended) The method [use according to any one] of claim[s] 19 [to 26] wherein the [oligonucleotides or] polynucleotides are [transferred] introduced into a cell[s] in culture.

31. (Amended) [The use of a spermine:peptide-based surfactant compound of any one of claims 1 to 18 to facilitate the transfer of a polynucleotide or an anti-infective compounds into prokaryotic or eukaryotic organism for use in anti-infective therapy] A method introducing a polynucleotide or anti-infective compound into a prokaryotic or eukaryotic organism for use in anti-infective therapy, the method comprising contacting the organism with the compound of claim 1 and a polynucleotide or anti-infective compound.

Novel compounds

This invention relates to newly identified spermine:peptide-based surfactant compounds, to the use of such compounds and to processes for their preparation. The invention also relates to the use of the spermine:peptide-based surfactant compounds to facilitate the transfer of compounds into cells for drug delivery.

Surfactants are substances that markedly affect the surface properties of a liquid, even at low concentrations. For example surfactants will significantly reduce surface tension when dissolved in water or aqueous solutions and will reduce interfacial tension between two liquids or a liquid and a solid. This property of surfactant molecules has been widely exploited in industry, particularly in the detergent and oil industries. In the 1970s a new class of surfactant molecule was reported, characterised by two hydrophobic chains with polar heads which are linked by a hydrophobic bridge (Deinega,Y *et al.*, *Kolloidn. Zh.* **36**, 649, 1974). These molecules, which have been termed "gemini" (Menger, FM and Littau,CA, *J.Am.Chem.Soc.* **113**, 1451, 1991), have very desirable properties over their monomeric equivalents. For example they are highly effective in reducing interfacial tension between oil and water based liquids and have a very low critical micelle concentration.

Cationic surfactants have been used *inter alia* for the transfection of polynucleotides into cells in culture, and there are examples of such agents available commercially to scientists involved in genetic technologies (for example the reagent Tfx^{TM}-50 for the transfection of eukaryotic cells available from Promega Corp. WI, USA).

The efficient delivery of DNA to cells *in vivo*, either for gene therapy or for antisense therapy, has been a major goal for some years. Much attention has concentrated on the use of viruses as delivery vehicles, for example adenoviruses for epithelial cells in the respiratory tract with a view to corrective gene therapy for cystic fibrosis (CF). However, despite some evidence of successful gene transfer in CF patients, the adenovirus route remains problematic due to inflammatory side-effects and limited transient expression of the transferred gene. Several alternative methods for *in vivo* gene delivery have been investigated, including studies using cationic surfactants. Gao,X *et al.* (1995) *Gene Ther.* **2**, 710-722 demonstrated the feasibility of this approach with a normal human gene for CF transmembrane conductance regulator (CFTR) into the respiratory epithelium of CF mice

using amine carrying cationic lipids. This group followed up with a liposomal CF gene therapy trial which, although only partially successful, demonstrated the potential for this approach in humans (Caplen, NJ. *et al., Nature Medicine*, 1, 39-46, 1995). More recently other groups have investigated the potential of other cationic lipids for gene delivery, for example cholesterol derivatives (Oudrhiri,N *et al. Proc.Natl.Acad.Sci.* **94**, 1651-1656, 1997). This limited study demonstrated the ability of these cholesterol based compounds to facilitate the transfer of genes into epithelial cells both *in vitro* and *in vivo*, thereby lending support to the validity of this general approach.

These studies, and others, show that in this new field of research there is a continuing need to develop novel low-toxicity surfactant molecules to facilitate the effective transfer of polynucleotides into cells both *in vitro* for transfection in cell-based experimentation and *in vivo* for gene therapy and antisense treatments. The present invention seeks to overcome the difficulties exhibited by existing compounds.

The invention relates to spermine:peptide-based surfactant compounds having a spermine backbone and having the general structure of formula (I):



(I)

where R_1 and R_3 are hydrogen and R_2 and R_4, which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):

$$-(A1)_{p1}-(A2)_{p2}-(A3)_{p3}$$

$(A4)_{p4}$ (II)

where p1 is 0 to 5 and p2 is 1 to 5, preferably 1; and the values for p3 and p4, which may be the same or different, are from 0 to 5, preferably 0;

A1, A3 and A4, which may be the same or different, are amino acids selected from serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and

A2 is an amino acid selected from lysine, ornithine and histidine;

and R_5 and R_6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH_2) linkage;

or

where R_1 and R_3 are hydrogen, R_2 and R_4, which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by amide or amine bonds, and R_5 and R_6, which may be the same or different, are peptide groups of formula (II) linked to the spermine backbone by amide bonds;

or

a salt, preferably a pharmaceutically acceptable salt thereof.

When used herein, the term "hydrocarbyl" refers to a group having from 1 to 24 carbon atoms which may be in a straight chain or a branched chain and include a saturated carbocyclic ring having from 3 to 6 carbon atoms and which chain may contain unsaturation (double and/or triple carbon-carbon bonds).

The amide linkages between the amino acids A1, A2 and A3 in the peptide group of formula (II) are standard peptide bonds (α bonds), unless the amino acid is a diamine, for example lysine or ornithine, where the linkage may involve either of the two amine groups. For example, where A1 is lysine, the linkage to the amino acid A2 may be a standard alpha amide bond, or an epsilon (ε) amide bond involving the amine of the lysine side chain. Similarly where A1 is ornithine the amide bond linking A1 to A2 may be an alpha bond or a delta (δ) bond that is created using the amine on the side chain of the ornithine amino acid residue.

Preferably, the compound is symmetrical, that is R_1 and R_3 are the same, R_2 and R_4 are the same, and R_5 and R_6 are the same. Symmetrical spermine:peptide-based surfactant compounds of the invention are "gemini" surfactants.

In a preferred embodiment A1 in the group of formula (II) is serine or threonine, prefereably serine. Preferably A3 and A4 in the group of formula (II) are lysine, ornithine, histidine or arginine.

In a further preferred embodiment the hydrocarbyl group is selected from:

$-CO(CH_2)_{10}CH_3$
$-CO(CH_2)_{12}CH_3$
$-CO(CH_2)_{14}CH_3$
$-CO(CH_2)_{16}CH_3$
$-CO(CH_2)_{18}CH_3$
$-CO(CH_2)_{22}CH_3$
$-CO(CH_2)_7CH=CH(CH_2)_5CH_3$
$-CO(CH_2)_7CH=CH(CH_2)_7CH_3$
$-CO(CH_2)_7CH=CHCH_2CH=CH(CH_2)_4CH_3$
$-CO(CH_2)_7(CH=CHCH_2)_3CH_3$
$-CO(CH_2)_3CH=CH(CH_2CH=CH)_3(CH_2)_4CH_3$
$-CO(CH_2)_7CH=CH(CH_2)_5CH_3$ Trans
$-CO(CH_2)_7CH=CH(CH_2)_7CH_3$ Trans
$-CO(CH_2)_8CHCH_3(CH_2)_7CH_3$
$-COCHOH(CH_2)_{21}CH_3$



In another preferred embodiment the hydrocarbyl group is selected from:

$-(CH_2)_{11}CH_3$
$-(CH_2)_{13}CH_3$
$-(CH_2)_{15}CH_3$
$-(CH_2)_{17}CH_3$
$-(CH_2)_{19}CH_3$
$-(CH_2)_{23}CH_3$
$-(CH_2)_8CH=CH(CH_2)_5CH_3$
$-(CH_2)_8CH=CH(CH_2)_7CH_3$
$-(CH_2)_8CH=CHCH_2CH=CH(CH_2)_4CH_3$
$-(CH_2)_8(CH=CHCH_2)_3CH_3$
$-(CH_2)_4CH=CH(CH_2CH=CH)_3(CH_2)_4CH_3$
$-(CH_2)_8CH=CH(CH_2)_5CH_3$ Trans
$-(CH_2)_8CH=CH(CH_2)_7CH_3$ Trans
$-(CH_2)_9CHCH_3(CH_2)_7CH_3$

Compounds of the present invention may be prepared from readily available starting materials using synthetic peptide chemistry well known to the skilled person. The scheme shown in Figures 1a and 1b shows a general process for the synthesis of the compounds of the invention wherein the hydrocarbyl groups are linked to the spermine moiety by amine bonds and the scheme shown in Figures 2a and 2b shows a general process for the synthesis of the compounds of the invention wherein the carbonyl groups are linked to the spermine moiety by amide bonds.

The processes shown in Figures 1 and 2 are for the synthesis of symmetrical, that is "gemini", spermine:peptide-based surfactants. Non-symmetrical spermine:peptide-based surfactants of the invention can be prepared by introducing asymmetry, for example at the primary amines of spermine, by using different protecting groups. Suitable nitrogen protecting groups are well known in the art and are described in, for example, "Protective Groups in Organic Chemistry" (T.W.Greene, Wiley-Interscience, New York, 2nd Edition, 1991).

Another aspect of the invention relates to methods for using the spermine:peptide-based surfactant compounds. Such uses include facilitating the transfer of DNA or RNA polynucleotides, or analogs thereof, into a eukaryotic or prokaryotic cell *in vivo* or *in vitro*. These uses include facilitating transfection of polynucleotides to achieve an antisense knock-out effect, for gene therapy and genetic immunisation (for the generation of

antibodies) in whole organisms. Other uses include employing the compounds of the invention to facilitate the transfection of polynucleotides into cells in culture when such transfer is required, in, for example, gene expression studies and antisense control experiments among others. The polynucleotides can be mixed with the compounds, added to the cells and incubated to allow polynucleotide uptake. After further incubation the cells can be assayed for the phenotypic trait afforded by the transfected DNA, or the levels of mRNA expressed from said DNA can be determined by Northern blotting or by using PCR-based quantitation methods for example the Taqman® method (Perkin Elmer, Connecticut, USA). Compounds of the invention offer a significant improvement, typically between 3 and 6 fold, in the efficiency of cellular uptake of DNA in cells in culture, compared with compounds in the previous art. In the transfection protocol, the gemini compound may be used in combination with one or more supplements to increase the efficiency of transfection. Such supplements may be selected from, for example:

(i) a neutral carrier, for example dioleyl phosphatidylethanolamine (DOPE) (Farhood, H., *et al* (1985) *Biochim. Biophys. Acta* 1235 289);

(ii) a complexing reagent, for example the commercially available PLUS reagent (Life Technologies Inc. Maryland, USA) or peptides, such as polylysine or polyornithine peptides or peptides comprising primarily, but not exclusively, basic amino acids such as lysine, ornithine and/or arginine. The list above is not intended to be exhaustive and other supplements that increase the efficiency of transfection are taken to fall within the scope of the invention.

In still another aspect, the invention relates to the transfer of genetic material in gene therapy using the compounds of the invention.

Yet another aspect of the invention relates to methods to effect the delivery of non-nucleotide based drug compounds into cells *in vitro* and *in vivo* using the compounds of the invention.

In a further aspect, the invention relates to methods to facilitate the transfer of a polynucleotide or an anti-infective compounds into prokaryotic or eukaryotic organism for use in anti-infective therapy.

The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"Amino acid" refers to dipolar ions (zwitterions) of the form $^{+}H_3NCH(R)CO_2^{-}$. They are differentiated by the nature of the group R, and when R is different from hydrogen can also be asymmetric, forming D and L families. Amino acids may be natural or un-natural amino acids. There are 20 naturally occurring amino acids where the R group can be, for example, non-polar (e.g. alanine, leucine, phenylalanine) or polar (e.g. glutamic acid, histidine, arginine and lysine). In the case of un-natural amino acids R can be any other group which is not found in the amino acids found in nature.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications have been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Transfection" refers to the introduction of polynucleotides into cells in culture using methods involving the modification of the cell membrane either by chemical or physical means. Such methods are described in, for example, Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). The polynucleotides may be linear or circular, single-stranded or double-stranded and may include elements controlling replication of the polynucleotide or expression of homologous or heterologous genes which may comprise part of the polynucleotide.

The invention will now be described by way of the following examples.

EXAMPLES

Example 1 – synthesis of GSC1

Step 1:



A solution of *N*-carbethoxyphthalimide (4 mmol, 439 mg) in chloroform (5 ml) was added as one portion at room temperature to a stirred solution of spermine (2 mmol, 406.7 mg) in chloroform (5 ml). The mixture was stirred for 1 hour and the solvent was removed, the crude was dried under good vacuum to get the title compound without further purification (Sosnovsky, G. (1986) Zeitschrift für Naturforschung **41b**:122-129).

Step 2:



The protected spermine 350 mg (0.76 mmol) was dissolved in 10 ml of dry THF, the Lauroyl chloride 3 eq (2.28 mmol) and 2 ml of dry pyridine was added. After refluxing 30 min, the mixture was stirred at room temperature overnight. Solvent was removed, and the crude was dissolved in AcOEt (25 ml) and was washed with saturated bicarbonate (2x20 ml). The organic phase was dried over anhydrous sodium sulfate and

evaporated. The resulting oil was chromatographied on silica gel with AcOEt/hexane (1:1 to 4:1) rf = 0.20 (AcOEt/hexane 1:1) to yield 490 mg (84 %) of bis-dodecyl as oil which crystallized as white semi-solid crystal. ^{1}H-NMR ($CDCl_3$): 7.9-7.6 *m* (8H (-C_6H_4-)2); 3.7-3.6 *m* (4H); 3.4-3.2 *m* (8H); 2.3-2.1 *m* (4H); 2.0-1.8 *m* (4H);1.6-1.4 *m* (8H); 1.3-1.1 *m* (32H); 0.9-0.8 *m* (6H). ^{13}C-NMR ($CDCl_3$): 173.1, 173.0, 172.9, 172.8, 168.3, 168.2, 134.2, 134.1, 133.9, 133.8, 132.2, 132.1, 132.0, 131.9, 123.4, 123.2, 47.6, 45.7, 45.5, 45.4, 43.5, 43.4, 35.9, 33.9, 33.2, 33.1, 30.9, 29.6, 29.5, 29.4, 29.3, 29.1, 28.3, 28.2 ,27.1, 26.7, 26.4, 25.5, 25.4, 25.2, 25.1, 24.9, 22.7, 14.1

Step 3:



The bis-phthalimide (400 mg, 0.48 mmol) was dissolved in 20 ml of MeOH, hydrazine monohydrate 0.4 ml was added and the mixture was refluxed 6 H. Solvent was removed, and the crude redissolved in MeOH (20 ml) and 2 ml of concentrated HCl was added. The mixture was refluxed for 30 min, and solvent was removed. The residue was dissolved in aqueous NaOH 10 %, the precipitate was filtrated and wash with 3 amount of cold water. The residue was dried to give 112 mg (41 %) of white powder. ^{1}H-NMR (MeOH): 3.21 *t* (^{3}J = 6.8Hz, 4H); 2.6-2.5 *m* (8H); 2.76 *t* (^{3}J = 7.5Hz, 4H); 1.7-1.5 *m* (12H); 1.4-1.2 *m* (32H); 0.89 *t* (^{3}J = 6.9Hz, 6H (-CH_3)2).

Step 4:



The diamine 100 mg (0.176 mmol), HOBt 2 eq (0.353 mmol, 54 mg), BOC_2Lys 2.4 eq (0.423 mmol, 135mg) and DIPEA 2 eq (0.353 mmol, 62 ml) was dissolved in CH_2Cl_2 (20 ml). The mixture was cooled at -10 °C and DCC 2.4 eq (0.423mmol, 87 mg) was

added. The mixture was stirred at -10 °C and allowed to reach room temperature very slowly and set aside overnight. The DCU was removed by filtration, and solvent was evaporated off. The crude was redissolved in AcOEt (30 ml), was washed successively 4 % $NaHCO_3$ (2 X 15 ml), 4 % citric acid (2 X 15 ml), water (20 ml) and finally brine (20 ml). Organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness. The residue was chromatographied on silica gel and was eluated with hexane/AcOEt 1/1 (rf = 0.01) to AcOEt/MeOH 9/1 (rf = 0.6) yield 152 mg (71 %) as oil. ^{1}H-NMR ($CDCl_3$): 7.05 sbroad(1H); 6.69 sbroad (1H); 5.6-4.7 m (6H); 4.9-4.1 *m* (4H); 3.7-3.0 *m* (16H); 2.2-2.0 *m* (6H); 2.0-1.0 *m* (88H); 0.88 *t* (^{3}J = 6.8Hz, 6H ($-CH_3)_2$).

Step 5:



The tetra-protected Gemini 150 mg (0.12 mmol) was dissolved in CH_2Cl_2/TFA 1/1 (25 ml) and was stirred at room temperature for 0.5 H. Solvent was removed to give the deprotected compounds as a TFA salt which was exchanged on anionic Dowex 1X8 to get the tetrahydrochloride salt as a sticky oil. The compound was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated three times, to give GSC1 . ^{1}H-NMR (MeOH): 3.8-3.1 *m* (8H); 3.0-2.8 *m* (4H); 2.2-2.1 *m* (4H); 2.0-1.4 *m* (26H); 1.4-1.2 *m* (36H); 0.90 *t* (^{3}J = 6.8Hz, 6H ($-CH_3)_2$). M/z(H^+): 823.75; ($2H^+$): 412.38.

Example 2 – Synthesis of GSC4

Step 1:



The diamine 150 mg (0.265 mmol) was dissolved in 5 % aqueous acetonitrile (10 ml) and triethylamine 2.2 eq (0.6 mmol, 80 µl) was added. The *Nα,Nε*-bis-*ter*-butyl-carbamate-L-lysine-L-serine-*O*-succinimidate (was built by the usual peptide synthesis) 2 eq (0.528 mmol, 280 mg) in acetonitrile (8 ml) was added slowly. The mixture was stirred 48 H at room temperature, and solvent was removed. The crude was redissolved in AcOEt (30 ml), was washed successively water (2x20 ml), 3 % HCl (2x20 ml), water (20 ml) and finally brine (20 ml). Organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness, to yield 252 mg (68 %). ^{1}H-NMR ($CDCl_3$): 4.9-4.1 *m* (4H); 3.6-3.0 *m* (20H); 2.2-2.0 *m* (8H); 2.0-1.0 *m* (80H); 0.88 *t* (^{3}J = 6.8Hz, 6H ($-CH_3)_2$).

Step 2:



The tetra-protected Gemini 248 mg (0.177 mmol) was dissolved in THF/HClconc 1/1 (25 ml) and was stirred at room temperature for 1 H. Solvent was removed to give the deprotected compounds as a sticky dark oil which was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated several times, to yield 120 mg (60 %) GSC4 as pink powder. ^{1}H-NMR (MeOH): 4.0-3.9 *m* (2H); 3.5-3.2 *m* ; 3.1-2.9 *m* (4H); 2.5-2.3 *m* (4H); 2.3-2.1 *m* (1H); 2.0-1.5 *m* (20H); 1.4-1.2 *m* (32H); 0.90 *t* (^{3}J = 6.8Hz, 6H ($-CH_3)_2$).

Example 3 – Synthesis of GSC40

Step 1:



The diamine 120 mg (0.212 mmol), HOBt 2.5 eq. (0.53 mmol, 72 mg), (BOC_2Lys)Lys 2.5 eq. (0.53 mmol, 426 mg) and DIPEA 2.5 eq. (0.53 mmol, 92 µl) was dissolved in CH_2Cl_2/THF 1/1 (20 ml). The mixture was cooled at -10 °C and DCC 2.4 eq. (0.508 mmol, 105 mg) was added. The mixture was stirred at -10 °C and allowed to reach room temperature very slowly and set aside overnight. The DCU was removed by filtration, and the solvent was evaporated off. The crude product was redissolved in EtOAc (30 ml), was washed successively with 4 % $NaHCO_3$ (2 X 15 ml), 4 % citric acid (2 X 15 ml), water (20 ml) and finally brine (20 ml). the organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness. The residue was chromatographed on silica gel and was eluated with hexane/EtOAc 1/1 (rf = 0.01) to EtOAc/MeOH 9/1 (rf = 0.55) yield 210 mg (46 %) as oil. ^{1}H-NMR ($CDCl_3$): 4.9-4.6 *m* (2H); 4.1-3.9 *m* (4H); 3.5-2.9 *m* (16H); 2.3-2.1 *m* (2H); 1.9-1.0 *m* (164H); 0.88 *t* (^{3}J = 6.8Hz, 6H ($-CH_3$)2).

Step 2:



The octa-protected gemini 200 mg (0.094 mmol) was dissolved in THF/HClconc 1/1 (20 ml) and was stirred at room temperature for 1 H. The solvent was removed to give the deprotected compounds as a yellow oil which was redissolved in small amount of MeOH and precipitate with ether, the solvent was removed by decantation, this was repeated several times, to yield 130mg (85%) GSC40 as yellow powder.

Example 4 – Synthesis of GSC41

Step 1:



The diamine 200 mg (0.35 mmol) was dissolved in 5 % aqueous acetonitrile (20 ml) and triethylamine 2 eq. (0.7 mmol, 0.1 ml) was added. The bis-(*Nα,Nε*-bis-*ter*-butyl-carbamate-L-lysine)-L-lysine-L-serine-*O*-succinimidate 2 eq (0.71 mmol, 700 mg) in acetonitrile (10 ml) was added slowly. The mixture was stirred 48 H at room temperature, and solvent was removed. The crude product was redissolved in AcOEt (30 ml), was washed successively water (2x20 ml), 3 % HCl (2x20 ml), water (20 ml) and finally brine (20 ml). The organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness, to yield 509 mg (63 %). ^{1}H-NMR ($CDCl_3$): 4.9-4.6 *m* ; 4.1-3.9 *m* (4H); 3.6-2.9 *m* (22H); 2.3-2.1 *m* (4H); 2.0-1.0 *m* ; 0.88 *t* (^{3}J = 6.8Hz, 6H ($-CH_3$)2).

Step 2:



. HCl 8

The tetra-protected gemini 499 mg (0.216 mmol) was dissolved in THF/HClconc 1/1 (30 ml) and was stirred at room temperature for 1 H. the solvent was removed to give the deprotected compounds as a sticky brawn oil which was redissolved in small amount of MeOH and precipitated with ether, solvent was removed by decantation, this was repeated several times, to yield 350mg (90%) GSC41 as brown powder.

Example 5 – Synthesis of GSC42

Step 1:



The diamine 200 mg (0.35 mmol) was dissolved in 5 % aqueous acetonitrile (20 ml) and triethylamine 2 eq. (0.7 mmol, 0.1 ml) was added. The bis-(*Nα,Nε*-bis-*ter*-butyl-carbamate-L-lysine)-L-lysine-L-serine-*O*-succinimidate 2 eq (0.71 mmol, 700 mg) in acetonitrile (10 ml) was added slowly. The mixture was stirred 48 H at room temperature, and solvent was removed. The crude product was redissolved in AcOEt (30 ml), was washed successively water (2x20 ml), 3 % HCl (2x20 ml), water (20 ml) and finally brine (20 ml). The organic phase was dried over anhydrous sodium sulfate and evaporated to dryness, to yield 522 mg (70 %). ^{1}H-NMR ($CDCl_3$): 6.7-6.6 *m* (2H); 5.5-5.3 *m* (2H); 4.9-4.6 *m* (4H); 4.5-4.3 *m* (4H); 4.1-3.9 *m* (4H); 3.5-2.9 *m* (20H); 2.3-2.1 *m* (4H); 1.9-1.0 *m* ; 0.88 *t* (^{3}J = 6.8Hz, 6H $(-CH_3)_2$).

Step 2:



. HCl 8

The tetra-protected Gemini 517 mg (0.242 mmol) was dissolved in THF/HClconc 1/1 (30 ml) and was stirred at room temperature for 1 H. The solvent was removed to give the deprotected compounds as a sticky dark oil which was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated several times, to yield 346mg (88%) GSC42 as brown powder.

Example 6 – Synthesis of GSC2

Step 1:



The protected spermine 1.23 g (2.65 mmol) was dissolved in 1,2-dichloroethane (25 ml) and dodecyl aldehyde 2.5 eq. (6.6 mmol, 1.5 ml) was added. After 10 mn, the sodium cyanoborohydride 6 eq. (15.9 mmol, 1 g) was added and the mixture was stirred at room temperature overnight. Then sodium cyanoborohydide 4.5 eq. (750 mg) was added again and mixture was stirred overnight at room temperature. This solution was partitioned between dichloromethane (150 ml) and water (150 ml) and the pH was adjusted to 9. The resulting emulsion was left in a separating funnel for 12 H. Then, the organic phase was dried over sodium sulfate and concentrated. The crude product was chromatographed on silica gel, eluated with EtOAc/Hexane 1/4 to 1/2 (rf: 0.3) containing 0.1% of NEt_3, to yield 540 mg of semi-solid yellow compound (26 %).

Step 2:



The protected spermine 200 mg (0.25 mmol) was dissolved in methanol (10 ml) and hydrazine monohydrate 10 eq (2.5 mmol, 0.13 ml) was added. The mixture was refluxed for 8 H, and the solvent was removed. The crude product was redissolved in 10 ml of methanol and conc. HCl (2 ml) was added, the mixture was refluxed for 30 min, cooled in ice and filtered. The solvent was removed and the crude product redissolved in dichloromethane (30 ml), stirred 30 min at room temperature and the precipate was removed by filtration. The solution was evaporated and dried under reduce pressure to yield 150 mg GSC2 as a yellow semi-solid compound (88 %).

Example 7 – Synthesis of GSC12

Step 1:



The diamine 143 mg (0.265 mmol) was dissolved in 5 % aq. THF (10 ml) and NEt3 0.6 mmol (80 ml), activated peptide 2 eq (0.528 mmol, 282 mg) in THF (5 ml) were added. The mixture was stirred overnight and concentrated. Then, the crude product was dissolved in EtOAc (60 ml) and was washed successively with water (2x20 ml) 3 % HCl (2x20 ml) water (20 ml) brine (20 ml). The organic phase was dried over sodium sulfate and the solvent was evaporated to yield 210 mg of a sticky white compound (58 %).

Step 2:



The tetra-Boc 200 mg (0.146 mmol) was dissolved in THF/conc. HCl 1/1 (20 ml) and was stirred at room temperature for 1 H. The solvent was removed and the crude product was redissolved in small amount of MeOH and precipitated with ether, cooled to -20 °C, the solvent was removed by decantation, this was repeated several times, to yield 150 mg (87 %) GSC12 as a yellow powder.

Example 8. Transfection of recombinant plasmid expressing luciferase into cells using spermine:peptide-based surfactant compounds.

Transfection studies were performed using the adherent cell line CHO-K1 (Puck et al. 1958). Complete medium consisted of MEM alpha medium supplemented with 10 % v/v foetal bovine serum and 1x L-Glutamine. All media and supplements were obtained from Life Technologies.

Stable transfected cell lines expressing β–galactosidase were generated by cotransfection of the plasmid pSV-β-Galactosidase Control Vector (Promega) with the plasmid Selecta Vecta-Neo (R & D Systems) in a 10:1 ratio. Following G418 (Life

Technologies) selection (0.8 mg ml^{-1}), candidate cell lines were tested for β–galactosidase activity (β–Gal Reporter Gene Assay, chemiluminescent; Roche Diagnostics).

***In Vitro* Gene Transfection.**

Cells were seeded into 96-well MTP plates (Beckton Dickinson) 16-18 hours prior to transfection at an approximate density of 1 x 10^4 cells per well. For transfection, 64ng of the luciferase reporter gene plasmid, pGL3-Control Vector (Promega) per well, was incubated with various concentrations of the spermine:peptide-based surfactant compounds and complexing agents. After 30 minutes incubation at RT, OPTI-MEM® medium (Life Technologies) was added to the transfection mixture and the solution placed on the cells (final volume per well: 100 µl). Following a 3 hour or over night incubation at 37°C, the transfection solution was replaced with complete medium and the cells incubated further at 37°C. Reporter gene assays were performed according to the manufacturer's guidelines (Roche Diagnostics) approximately 48 hours post transfection. Luminescence was measured in a Packard TopCount NXT Microplate Scintillation and Luminescence Counter. For normalization purpose, β–galactosidase activity (β–Gal Reporter Gene Assay, chemiluminescent; Roche Diagnostics) was measured and luciferase activity per β–galactosidase activity was calculated.

Brief description of the drawings

Figure 1a and Figure 1b. General sheme for synthesis of spermine:peptide-based surfactant compounds wherein the carbonyl groups (in this instance dodecanoyl) are linked to the spermine moiety by amide bonds. The final compound in Fig 1a is the first compound in Fig 1b.

Figure 2a and Figure 2b. General sheme for synthesis of spermine:peptide-based surfactant compounds wherein the carbonyl groups (in this instance dodecanoyl) are linked to the spermine moiety by amine bonds. The final compound in Fig 2a is the first compound in Fig 2b.

Figure 3. Transfection of CHO-K1 cells (stable transfected with beta-galactosidase) with spermine:peptide-based gemini surfactants GS-C-1, GS-C-2, GS-C-3, GS-C-4, and GS-C-12. Bars represent the mean cps (counts per second) of 8 experiments ± the standard error of the mean.

CLAIMS

1. A spermine:peptide-based surfactant compound having the general structure of formula (I):



(I)

where R_1 and R_3 are hydrogen and R_2 and R_4, which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):

$$-(A1)_{p1}-\underset{\underset{\displaystyle (A4)_{p4}}{|}}{(A2)_{p2}}-(A3)_{p3} \qquad \text{(II)}$$

where p1 is 0 to 5 and p2 is 1 to 5; and the values for p3 and p4, which may be the same or different, are from 0 to 5;
A1, A3 and A4, which may be the same or different, are amino acids selected from serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and
A2 is an amino acid selected from lysine, ornithine and histidine;
and R_5 and R_6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH_2) linkage;
or
where R_1 and R_3 are hydrogen, R_2 and R_4, which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the

spermine backbone by amide or amine bonds, and R_5 and R_6, which may be the same or different, are peptide groups of formula (II) linked to the spermine backbone by amide bonds;

or

a salt, preferably a pharmaceutically acceptable salt thereof.

2. A spermine:peptide-based surfactant compound according to claim 1 which is symmmetrical, that is R_1 and R_3 are the same, R_2 and R_4 are the same, and R_5 and R_6 are the same.

3. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (II) p1 is 1 and p2, p3 and p4 are all 0.

4. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (II) p1 and p2 are both 1 and p3 and p4 are both 0.

5. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (II) p1 is 0 and p2, p3 and p4 are all 1.

6. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (II) p1 and p3 are 0, p2 is 1 and p4 is 2.

7. A spermine:peptide-based surfactant compound according to any one of claims 1 to 6 wherein the A1 is serine.

8. A spermine:peptide-based surfactant compound according to any one of claims 1 to 6 wherein the A2 is lysine.

9. A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from:

—$(CH_2)_{11}CH_3$
—$(CH_2)_{13}CH_3$
—$(CH_2)_{15}CH_3$
—$(CH_2)_{17}CH_3$
—$(CH_2)_{19}CH_3$
—$(CH_2)_{23}CH_3$
—$(CH_2)_8CH{=}CH(CH_2)_5CH_3$
—$(CH_2)_8CH{=}CH(CH_2)_7CH_3$
—$(CH_2)_8CH{=}CHCH_2CH{=}CH(CH_2)_4CH_3$
—$(CH_2)_8(CH{=}CHCH_2)_3CH_3$
—$(CH_2)_4CH{=}CH(CH_2CH{=}CH)_3(CH_2)_4CH_3$
—$(CH_2)_8CH{=}CH(CH_2)_5CH_3$ Trans
—$(CH_2)_8CH{=}CH(CH_2)_7CH_3$ Trans
—$(CH_2)_9CHCH_3(CH_2)_7CH_3$

10. A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from:

—$CO(CH_2)_{10}CH_3$
—$CO(CH_2)_{12}CH_3$
—$CO(CH_2)_{14}CH_3$
—$CO(CH_2)_{16}CH_3$
—$CO(CH_2)_{18}CH_3$
—$CO(CH_2)_{22}CH_3$
—$CO(CH_2)_7CH{=}CH(CH_2)_5CH_3$
—$CO(CH_2)_7CH{=}CH(CH_2)_7CH_3$
—$CO(CH_2)_7CH{=}CHCH_2CH{=}CH(CH_2)_4CH_3$
—$CO(CH_2)_7(CH{=}CHCH_2)_3CH_3$
—$CO(CH_2)_3CH{=}CH(CH_2CH{=}CH)_3(CH_2)_4CH_3$
—$CO(CH_2)_7CH{=}CH(CH_2)_5CH_3$ Trans
—$CO(CH_2)_7CH{=}CH(CH_2)_7CH_3$ Trans
—$CO(CH_2)_8CHCH_3(CH_2)_7CH_3$
—$COCHOH(CH_2)_{21}CH_3$
—$CO(CH_2)_9CH$—$CH(CH_2)_5CH_3$
CH_2
$COCH$—$(CH_2)_{10}CH_3$
$CO(CH_2)_{12}CH_3$

11. The compound:



12. The compound:



13. The compound GSC1 of formula:



. HCl 4

14. The compound GSC4 of formula:



. HCl 4

15. The compound GSC40 of formula:



16. The compound GSC42 of formula:



17. The compound GSC2 of formula:



18. The compound GSC12 of formula:



19. The use of a spermine:peptide-based surfactant compound as defined in any one of claims 1 to 15 in facilitating transfection of DNA or RNA polynucleotides or analogs thereof into a eukaryotic or prokaryotic cell *in vivo* or *in vitro*.

20. The use of a spermine:peptide-based surfactant compound according to claim 19 wherein the compound is used in combination with one or more supplements selected from the group consisting of:
(i) a neutral carrier; or
(ii) a complexing reagent.

21. The use according to claim 20 wherein the neutral carrier is dioleoyl phosphatidylethanolamine (DOPE).

22. The use according to claim 20 wherein the complexing reagent is PLUS reagent.

23. The use according to claim 20 wherein the complexing reagent is a peptide comprising mainly basic amino acids.

24. The use according to claim 23 wherein the peptide consists of basic amino acids.

25. The use according to claim 23 or 24 wherein the basic amino acids are selected from lysine and arginine.

26. The use according to claim 24 wherein the peptide is polylysine or polyornithine.

27. The use according to any one of claims 19 to 26 wherein the oligonucleotides or polynucleotides are transferred into cells to achieve an antisense knock-out effect.

28. The use according to claim 19 wherein the oligonucleotides or polynucleotides are transferred into cells for gene therapy.

29. The use according to claim 19 wherein the oligonucleotides or polynucleotides are transferred into cells for genetic immunisation (for the generation of antibodies) in whole organisms.

30. The use according to any one of claims 19 to 26 wherein the oligonucleotides or polynucleotides are transferred into cells in culture.

31. The use of a spermine:peptide-based surfactant compound of any one of claims 1 to 18 to facilitate the transfer of a polynucleotide or an anti-infective compounds into prokaryotic or eukaryotic organism for use in anti-infective therapy.

32. The use of a spermine:peptide-based surfactant compound of any one of claims 1 to 18 to facilitate the adhesion of cells in culture to each other or to a solid or semi-solid surface.

33. A process for preparing spermine:peptide-based surfactant compounds of claim 1 which process comprises adding amino acids or peptides to a hydrocarbylated spermine backbone.

Abstract

Spermine:peptide-based surfactant compounds are disclosed. The compounds are based on a spermine backbone with peptide groups and optionally hydrocarbyl groups linked thereto. Uses of the spermine:peptide-based surfactant compounds and methods for their production are also disclosed.

Figure 1a


26%
Dodecyl aldehyde
NaBHOAc, MeOH
88%
1) Hydrazine monohydrate
MeOH reflux
2) HCl MeOH reflux
$C_{11}H_{23}$
$C_{11}H_{23}$
. HCl 4

Figure 1b


H2N
N
N
NH2
C11H23
C11H23
. HCl 4
(AA3)n" — (AA2)n' — (AA1)n — R
(AA4)n'''
R = —O—N
O
O
THF or Acetonitrile, 5% H2O
C11H23
(AA3)n" — (AA2)n' — (AA1)n — H N
(AA4)n'''
N
N
N H — (AA1)n — (AA2)n' — (AA3)n"
C11H23
(AA4)n'''
quantitatively
THF/conc. HCl 1/1
C11H23
(AA3)n" — (AA2)n' — (AA1)n — H N
(AA4)n'''
N
N
N H — (AA1)n — (AA2)n' — (AA3)n"
C11H23
(AA4)n'''
. HCl 2x(n+n'+n"+n"')

Figure 2a


quantitative
N-Ethylcarboxyphtaloimide
CHCl3
95 %
Lauroyl Chloride,
THF, pyridine
41%
1) Hydrazine monohydrate, MeOH reflux
2) HCl reflux

Figure 2b


Method A: DCC, HOBt, DIPEA CH_2Cl_2
Method B: THF or Acetonitrile, 5% H2O
65-80%
R = OH in method A
method B
quantitatively
THF/conc. HCl 1/1

Figure 3


160000
140000
120000
100000
80000
60000
40000
20000
0
cps (mean of 8 experiments)
0 2 4 6 8 10 20 30 50
GS_C_1
GS_C_2
GS_C_3
GS_C_4
GS_C_12
µM

Docket No.: P32328

PCT/GB00/02364

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SPERMINE:PEPTIDE-BASED SURFACTANT COMPOUNDS

the specification of which (check one)

[ ] is attached hereto.

[X] was filed on 16 June 2000 as Serial No. PCT/GB00/02364
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9914045.1	Great Britain	16 June 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Elizabeth Hecht, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5009.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Patrick CAMILLERI

Inventor's Signature: P. Camilleri Date: 20-05-2002

Residence: Harlow, Essex, England GB2

Citizenship: Maltese

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: ~~Philippe~~ GUEDAT

Inventor's Signature: Ph. Guedat Date: 27-05-2002

Residence: Lyon, Cedex, France FR

Citizenship: French

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Anthony John KIRBY

Inventor's Signature: _____ Date: 30 May 2002

Residence: Cambridge, Cambridgeshire, England GB2

Citizenship: British

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Andreas KREMER

Inventor's Signature: _____ Date: 06/07/2002

Residence: ~~Harlow, Essex, England~~ GB2 Leverkusen, Germany

Citizenship: German

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939